Europe Thephase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple .
SanofiApril 19, 2021 GMT
European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma
Approval based on Phase 3 IKEMA study demonstrating Sarclisa added to standard of care carfilzomib and dexamethasone reduced risk of disease progression or death by 47% in patients who had relapsed after one to three prior therapies
Sarclisa combination therapy was associated with undetectable levels of multiple myeloma (MM) in nearly 30% of patients with relapsed MM
Second EU approval in less than 12 months for Sarclisa in combination with a standard of care regimen for the treatment of relapsed or refractory MM ....

France General , United States , United Kingdom , South Korea , Eva Schaefer Jansen , Suzanne Greco , Arnaud Delepine , Felix Lauscher , Philippe Moreau , Europe Thephase , Fara Berkowitz , Peterc Adamson , Sally Bain , University Hospital Of Nantes , International Myeloma Foundation , European Commission , Drug Administration , Department Of Hematology , Global Development Head , University Hospital , Pediatric Innovationatsanofi , Safety Profile , Nonproprietary Naming , Biological Products Guidance , Empowering Life , Private Securities Litigation Reform Act ,